Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workersClinical Trial Published on 2023-05-012023-06-24 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 신종인플루엔자, [키워드] clinical trial COVID-19 immunogenicity Influenza vaccination. [DOI] 10.1016/j.cmi.2022.12.008 PMC 바로가기 [Article Type] Clinical Trial
Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitorsArticle Published on 2023-03-212023-07-11 Journal: Journal of theoretical biology [Category] COVID19(2023년), [키워드] clinical trial COVID-19 SARS-CoV-2 Virus dynamics. [DOI] 10.1016/j.jtbi.2022.111403 PMC 바로가기
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trialRandomized Controlled Trial Published on 2023-03-162023-06-13 Journal: BMC Medicine [Category] B형 간염, Fulltext, [키워드] antiviral therapy clinical trial hepatitis B pharmacokinetics. [DOI] 10.1186/s12916-023-02814-w PMC 바로가기 [Article Type] Randomized Controlled Trial
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adultsClinical Trial Published on 2023-03-102023-07-11 Journal: Vaccine [Category] COVID19(2023년), [키워드] clinical trial COVID-19 vaccine immunogenicity preclinical study Recombinant spike protein Safety. [DOI] 10.1016/j.vaccine.2022.12.025 PMC 바로가기 [Article Type] Clinical Trial
A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19Randomized Controlled Trial Published on 2023-03-012023-07-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] clinical trial COVID-19 SARS-CoV-2 serine protease inhibitor Upamostat. [DOI] 10.1016/j.ijid.2022.12.003 PMC 바로가기 [Article Type] Randomized Controlled Trial
Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trialClinical Trial Published on 2023-03-012023-07-11 Journal: Journal of global antimicrobial resistance [Category] COVID19(2023년), [키워드] ARDS Cenicriviroc clinical trial COVID-19 SARS-CoV-2. [DOI] 10.1016/j.jgar.2022.12.004 PMC 바로가기 [Article Type] Clinical Trial
Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trialRandomized Controlled Trial Published on 2023-03-012023-07-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] Antiviral clinical trial COVID-19 Lopinavir Outpatient Ritonavir. [DOI] 10.1016/j.ijid.2022.12.028 PMC 바로가기 [Article Type] Randomized Controlled Trial
A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19Clinical Trial Published on 2023-01-242023-07-11 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), [키워드] antiviral agent Camostat mesylate clinical trial coronavirus disease 2019. SARS-CoV-2 [DOI] 10.1128/aac.00452-22 PMC 바로가기 [Article Type] Clinical Trial
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model마우스 모델에서 SARS-CoV-2 공격에 대한 보호 반응 유도에 대한 최적화된 서열과 SARS-CoV-2의 스파이크 단백질 야생형 DNA 서열의 비교Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 비임상, 진단, [키워드] acid Against Antiviral binding breath CD4 CD8+ cellular immune responses cellular immunity challenge clinical trial contributing to COVID-19 CTL demonstrated DNA DNA vaccine expression full-length spike protein hACE2 humoral humoral and cellular immunity IFN-γ immune immune responses immunogen in vitro induction mice Model mouse Neutralizing antibodies optimization optimizations pGX-9501 platform Protective Protective effects protective response RBD binding response robust SARS-CoV-2 sequence spike Spike protein subsequent T cell T cells the vaccine Transgenic mouse Type virus wild-type wild-type sequence. [DOI] 10.1080/21645515.2021.2016201 PMC 바로가기 [Article Type] Article
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & JohnsonSARS-CoV-2 백신에 대한 포괄적인 검토: Pfizer, Moderna & Johnson & JohnsonReview Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Adenovirus administration age approval clinical clinical trial clinical trials coronavirus coronavirus. COVID-19 COVID-19 vaccine COVID-19 vaccines effective Efficacy General population group Johnson Johnson & Johnson Johnson & large cohort mechanism moderate Moderna mRNA vaccines Novel coronavirus ongoing trial ongoing trials outbreak pandemic participant Pfizer Safety SARS-CoV-2 SARS-CoV-2 coronavirus SARS-COV-2 infection shown Side effects Spike protein symptomatic SARS-CoV-2 infection tested the SARS-CoV-2 the spike protein the United State Trial United States Vaccinations Vaccine vaccine administration variant [DOI] 10.1080/21645515.2021.2002083 PMC 바로가기 [Article Type] Review